Price$1.63+0.18 (+12.07%)
2026-03-052026-06-08
News · 26 weeks17-100%
2025-12-142026-06-07
Mix790d
- SEC Filings3(43%)
- Other2(29%)
- Insider2(29%)
Latest news
25 items- SECRafael Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Rafael Holdings, Inc. (0001713863) (Filer)
- PRRafael Holdings Announces Patent Licensing Agreement with MIT for "Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease"NEWARK, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today announced that its subsidiary, Cyclo Therapeutics, has entered into an exclusive licensing agreement with Massachusetts Institute of Technology ("MIT") covering U.S. Patent No.12285440. This license covers the use of cyclodextrins in patients with Alzheimer's Disease (AD) who carry an ApoE4 genetic mutation, strengthening the company's intellectual property portfolio around Trappsol® Cyclo™ in this important AD patient population. The ApoE4 gene variant is estimated to be present in 50-70% of patients with AD and is believed to be a key risk factor in the development early onset sporadic AD. Dysregulat
- INSIDERSEC Form 4 filed by Polinsky David4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- INSIDERExec Chairman, CEO & President Jonas Howard S covered exercise/tax liability with 9,826 units of Class B Common Stock, decreasing direct ownership by 3% to 323,014 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- SECSEC Form 10-Q filed by Rafael Holdings Inc.10-Q - Rafael Holdings, Inc. (0001713863) (Filer)
- SECRafael Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Rafael Holdings, Inc. (0001713863) (Filer)
- PRRafael Holdings Reports Second Quarter Fiscal 2026 Financial ResultsNEWARK, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today reported its financial results for the second quarter fiscal year 2026 ended January 31, 2026. "We remain pleased with the progress of our pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, which the Data Monitoring Committee (DMC) recommended continuing after their review of prespecified safety and efficacy data at 48 weeks. We believe that Trappsol® Cyclo™ could provide an important new treatment option for patients suffering from this rare and fatal genetic disease," said Howard Jonas, Chief Executive Officer, Executive Chairman and Cha
- INSIDERDirector Sieger Markus was granted 29,528 units of Class B Common Stock, increasing direct ownership by 16% to 219,710 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- INSIDERDirector Weiss Michael J was granted 39,370 units of Class B Common Stock, increasing direct ownership by 38% to 141,861 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- INSIDERDirector Stein Mark N was granted 39,370 units of Class B Common Stock, increasing direct ownership by 343% to 50,845 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- INSIDERDirector Grayson Alan was granted 6,562 units of Class B Common Stock (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- SECSEC Form S-8 filed by Rafael Holdings Inc.S-8 - Rafael Holdings, Inc. (0001713863) (Filer)
- INSIDERExec Chairman, CEO & President Jonas Howard S was granted 75,000 units of Class B Common Stock, increasing direct ownership by 29% to 332,840 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- INSIDERChief Financial Officer Polinsky David covered exercise/tax liability with 4,865 units of Class B Common Stock and was granted 50,000 units of Class B Common Stock, increasing direct ownership by 17% to 303,815 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- SECRafael Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Rafael Holdings, Inc. (0001713863) (Filer)
- INSIDERChief Financial Officer Polinsky David covered exercise/tax liability with 1,961 units of Class B Common Stock, decreasing direct ownership by 0.75% to 258,680 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- INSIDERExec Chairman, CEO & President Jonas Howard S covered exercise/tax liability with 9,867 units of Class B Common Stock, decreasing direct ownership by 4% to 257,840 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- SECSEC Form 10-Q filed by Rafael Holdings Inc.10-Q - Rafael Holdings, Inc. (0001713863) (Filer)
- SECRafael Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Rafael Holdings, Inc. (0001713863) (Filer)
- PRRafael Holdings Reports First Quarter Fiscal 2026 Financial ResultsNEWARK, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today reported its financial results for the first quarter fiscal year 2026 ended October 31, 2025. "We remain pleased with the progress of our pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, which the Data Monitoring Committee (DMC) recommended continuing after their review of prespecified safety and efficacy data at 48 weeks. We believe that Trappsol® Cyclo™ could provide an important new treatment option for patients suffering from this rare and fatal genetic disease," said Howard Jonas, Chief Executive Officer, Executive Chairman and Chair
- SECSEC Form 25-NSE filed by Rafael Holdings Inc.25-NSE - Rafael Holdings, Inc. (0001713863) (Subject)
- SECRafael Holdings Inc. filed SEC Form 8-K: Other Events8-K - Rafael Holdings, Inc. (0001713863) (Filer)
- SECSEC Form DEF 14A filed by Rafael Holdings Inc.DEF 14A - Rafael Holdings, Inc. (0001713863) (Filer)
- INSIDERNew insider Grayson Alan claimed no ownership of stock in the company (SEC Form 3)3 - Rafael Holdings, Inc. (0001713863) (Issuer)
- SECSEC Form 10-K filed by Rafael Holdings Inc.10-K - Rafael Holdings, Inc. (0001713863) (Filer)
RFL FAQ
6 questionsWhat does Rafael Holdings Inc. do?
Rafael Holdings, Inc. owns commercial real estate assets and interests in pre-clinical and clinical stage pharmaceutical companies. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.Where does RFL stock trade?
Rafael Holdings Inc. (RFL) is listed on NYSE.What sector and industry is RFL in?
Rafael Holdings Inc. operates in the Finance sector, Real Estate industry.When did Rafael Holdings Inc. go public?
Rafael Holdings Inc. (RFL) completed its IPO in 2018.What companies are similar to RFL?
Notable peers in the same industry include V (Visa Inc.), MA (Mastercard Incorporated), BABA (Alibaba Group Holding Limited), UBER (Uber Technologies Inc.), ACN (Accenture plc). Compare RFL side-by-side with any of them on Quantisnow.How can I track RFL on Quantisnow?
Quantisnow aggregates Rafael Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RFL to receive live email and push alerts on every new disclosure.